Updated: October 2018

Lamivudine/Zidovudine 150 mg/300 mg Tablets (Strides Pharma Science Ltd), HA291

LABELING

Updated: October 2018

Lamivudine/Zidovudine 150 mg/300 mg Tablets (Strides Pharma Science Ltd), HA291

PARTICULARS TO APPEAR ON THE OUTER PACKAGING OR, WHERE THERE IS NO OUTER PACKAGING, ON THE IMMEDIATE PACKAGING Bottle and carton label

1. NAME OF THE MEDICINAL PRODUCT

Lamivudine/Zidovudine 150 mg/300 mg Tablets¹

2. STATEMENT OF ACTIVE SUBSTANCE

Each tablet contains 600 mg efavirenz.

3. LIST OF EXCIPIENTS

See patient information leaflet for further information

4. PHARMACEUTICAL FORM AND CONTENTS

60 tablets

5. METHOD AND ROUTE OF ADMINISTRATION

Oral use

Read the package leaflet before use.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN

Keep out of the reach and sight of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP {MM/YYYY}

9. SPECIAL STORAGE CONDITIONS

Store below 30°C. Protect from light.

-

¹ Trade names are not prequalified by WHO. This is under local DRA responsibility. Throughout this WHOPAR the proprietary name is given as an example only.

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

Updated: October 2018

11. NAME AND ADDRESS OF THE SUPPLIER

Strides Pharma Science Limited Strides House Bilekahalli, Bannerghatta Road 560076 Bangalore Karnataka India

12. WHO REFERENCE NUMBER (PREQUALIFICATION PROGRAMME)

HA291

13. MANUFACTURER'S BATCH NUMBER

<Batch> <Lot> <BN> {number}

14. (ADVICE ON) GENERAL CLASSIFICATION FOR SUPPLY

Medicinal product subject to medical prescription.

15. INSTRUCTIONS ON USE